| Project/Area Number |
25860969
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
ITOH Munenari 東京慈恵会医科大学, 医学部, 講師 (20408371)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 人工多能性幹細胞 / 悪性黒色腫 / 養子免疫療法 |
|---|
| Outline of Final Research Achievements |
Our aim of this project is the establishment of effective adaptive immunotherapy for the treatment of malignant melanoma (MM) using induced pluripotent stem cell (iPSC). We first isolated and expanded tumor antigen-specific cytotoxic T cells from the patients with MM by our original protocol. We next generated iPSC from isolated cytotoxic T cell using sendai virus vector and/or episomal vector. Until now, two iPSC lines were obtained and the authenticity of these iPSCs was confirmed using several ways, indicating the possibility that enough amount of rejuvenated cytotoxic T cells would be provided for adaptive immunotherapy against MM, since the information of re-arranged T cell receptor gene should be kept even after generating iPSC.
In the future, we will attempt to re-differentiate iPSCs into cytotoxic T cells, and confirm these cytotoxic functions to reject tumor cells.
|
